Complement System
The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.
The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.
All Product Categories
-
Complement System Inhibitors
(133)
View all products
-
Complement System Agonists
(13)
View all products
-
Complement System Antagonists
(21)
View all products
-
Complement System Activators
(7)
View all products
-
Complement System Modulator
(1)
View all products
-
Complement System Controls
(2)
View all products
-
Complement System Ligands
(3)
View all products
-
Complement System Proteins
(113)
View all products
-
Complement System Verwandte Produkte (211)
Verwandte Produkte (211)
-
Recombinant Proteins (113)
-
Antibodies (7)
-
C5aR-IN-1
0 ImagesArt. -Nr.: HY-147585CAS. Nr.: 2761048-02-4C5aR-IN-1 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-1 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 47).
-
C1s-IN-1
0 ImagesArt. -Nr.: HY-W371164CAS. Nr.: 1016866-61-7C1s-IN-1 (compound A1) is a selective and competitive inhibitor of C1s. C1s-IN-1 binds directly to C1s with a Kd of 9.8 μM.
-
C5aR-IN-3
0 ImagesArt. -Nr.: HY-147587CAS. Nr.: 2761048-50-2C5aR-IN-3 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-3 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 89).
-
ASP-1948
0 ImagesArt. -Nr.: HY-P991329ASP-1948 is a human monoclonal antibody (mAb) targeting NRP1/VEGF165R/CD34. ASP-1948 reverses the suppressive effects of regulatory T cells. ASP-1948 can be used in solid tumors research.
-
Factor B-IN-8
0 ImagesArt. -Nr.: HY-181040CAS. Nr.: 3049710-19-9Factor B-IN-8 (Compound (3R ,4R )-15) is a potent, selective and orally active factor B inhibitor with an IC50 of 10.2 nM. Factor B-IN-8 can effectively inhibit the binding of factor B to C3b and the subsequent formation of C3 convertase (C3bBb). Factor B-IN-8 can inhibit the deposition of membrane attack complex (MAC) mediated by alternativepathway with an IC50 of 59.3 nM. Factor B-IN-8 can reduce the cleavage of factor B protein and decrease the deposition of complement C3d in the glomeruli and renal tubules. Factor B-IN-8 can be used for researches of arthritis and paroxysmal nocturnal hemoglobinuria (PNH).
-
CP-EPS8-NLS
0 ImagesArt. -Nr.: HY-P11076CP-EPS8-NLS is a peptide with anti-AML property. CP-EPS8-NLS interferes with EPS8-associated signaling and exerts anti-AML activity in various AML cell types. CP-EPS8-NLS has potent antitumor activity in xenograft tumor models. CP-EPS8-NLS downregulates EPS8 expression and its downstream pathway.
-
TLQP-21
0 ImagesArt. -Nr.: HY-P1345CAS. Nr.: 869988-94-3TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM). TLQP-21 activates C3aR1 to induce an increase of intracellular Ca2+. TLQP-21 is used for the research in regulation of nociception and other relevant physiologic functions.
-
Refinicopan
0 ImagesArt. -Nr.: HY-177123CAS. Nr.: 2922808-66-8
-
C1s Proenzyme
0 ImagesArt. -Nr.: HY-E70534C1s Proenzyme, the native form of C1s enzyme, is an inactive zymogen until C1 is activated. C1 complex binds to and is activated by antigen-antibody complexes (immune complexes) yielding C1r enzyme. C1r enzyme in the C1 complex activates C1s proenzyme generating C1s enzyme.
-
11-O-Methylpseurotin A
0 ImagesArt. -Nr.: HY-130043CAS. Nr.: 956904-34-011-O-Methylpseurotin A is a compound of mixed polyketide synthase–nonribosomal peptide synthetase (PKS/NRPS) origin. 11-O-Methylpseurotin A selectively inhibits a Hof1 deletion strain.
-
RPARPAR
0 ImagesArt. -Nr.: HY-P11647CAS. Nr.: 1184942-81-1RPARPAR is a CendR tumor-penetrating peptide. RPARPAR directly binds to the NRP-1 and NRP-2 receptors on the surface of tumor cells, triggering cellular internalization, vascular extravasation, and penetration into tumor tissues. RPARPAR serves as an efficient ligand for targeting nanocarriers to NRP-1-positive tumors. RPARPAR is applicable in research on tumor targeting and drug delivery.
-
C5aR-IN-2
0 ImagesArt. -Nr.: HY-147586CAS. Nr.: 2761048-06-8C5aR-IN-2 is a potent inhibitor of C5aR. Increased level of C5a has been associated with disorders such as autoimmune disorders and inflammatory disorders. C5aR-IN-2 has the potential for the research of inflammation diseases (extracted from patent WO2022028586A1, compound 49).
-
Compstatin control peptide TFA
0 ImagesArt. -Nr.: HY-P1398ACompstatin control peptide TFA is a negative control of Compstatin (HY-P1036). Compstatin is a potent complement system C3 inhibitor.
-
N-((Allyloxy)carbonyl)-N-methyl-L-alanine
0 ImagesArt. -Nr.: HY-W049802CAS. Nr.: 918531-01-8
-
Agazisiran sodium scrambled negative control
0 ImagesArt. -Nr.: HY-177611BAgazisiran sodium scrambled negative control is the sequence scrambled negative control of Agazisiran sodium.
-
Cyclosporin A-OVA
0 ImagesArt. -Nr.: HY-NP194ACyclosporin A-OVA is a conjugate of Cyclosporin A (HY-B0579) and OVA. Cyclosporin A is an immunosuppressant which binds to the cyclophilin .
-
Factor B-IN-3
0 ImagesArt. -Nr.: HY-147605CAS. Nr.: 2760669-74-5Factor B-IN-3 (Example 3 target compound) is a potent complement factor B inhibitor. Factor B-IN-3 can be used for the research of diseases related to inflammation and immunity.
-
GT103
0 ImagesArt. -Nr.: HY-P991954GT103 is a human-derived monoclonal antibody targeting complement factor H (CFH). GT103 binds to a conformationally distinct epitope of CFH on tumor cells. GT103 activates the classical complement pathway, induces complement-dependent cytotoxicity, and triggers antibody-dependent cellular phagocytosis (ADCP) of tumor cells. GT103 increases calreticulin translocation to tumor cell plasma membranes. GT103 mediates B-cell activation via Syk kinase phosphorylation. GT103 inhibits tumor growth and metastasis in animal models. GT103 can be used for the research of non-small cell lung cancer.
-
Vensobafusp alfa
0 ImagesArt. -Nr.: HY-P991067CAS. Nr.: 2724922-85-2Synonyms: KP-104Vensobafusp alfa (KP-104) is a fusion protein composed of an IgG4 monoclonal antibody directed against terminal complement protein C5 fused to the complement factor H 1-5 domain (FH1-5). Vensobafusp alfa shows anti-inflammatory and immunomodulatory activities. The isotype control for Vensobafusp alfa can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003)..
